Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Selective bladder denervation shows potential for treating refractory OAB in women

12 Oct 2018

Selective bladder denervation provides a minimally invasive treatment option for female patients with refractory overactive bladder (OAB), with data from two prospective feasibility studies showing that the intervention improves symptoms over 6 months of follow-up.

The total population comprised 35 women (mean age 66 years) with refractory OAB and urgency urinary incontinence (UUI) who received selective bladder denervation of the subtrigonal region containing afferent sensory nerves. Patients were followed for 6 months and evaluated for OAB symptoms, health-related quality of life measures and adverse events.

All selective bladder denervation procedures were successfully completed, and symptom improvements based on 3-day bladder diaries were seen over the follow-up period. Specifically, UUI improved by 59 percent from baseline (p<0.001), urinary incontinence by 59 percent (p<0.001), urgency by 39 percent (p<0.001), urinary frequency by 9 percent (p=0.01), and total urgency and frequency score by 27 percent (p<0.001). The majority of these treatment benefits were observed in as early as the first month following treatment.

The rate of clinical success, defined as ≥50-percent reduction in UUI, was 70 percent. Treatment benefit was reported in 75 percent of patients, and the dry/cure rate was 27 percent.

Additionally, statistically significant increases in health-related quality of life were observed over 6 months, as reflected on Symptom Bother and Health-related Quality of Life scales on the OAB questionnaire, as well as on all domains of King’s Health Questionnaire except general health perception.

In terms of safety, device- or procedure-related adverse events occurred in six patients (17 percent).

A minimally invasive selective bladder denervation device includes a disposable transurethral instrument that accepts a rigid endoscope for visualization and has a lumen to facilitate addition and removal of fluids in the bladder. At the end of the lumen is a suction paddle that works to stabilize of the tissue and deliver the radiofrequency electrodes. [Neurourol Urodyn 2018;37:2097-2105]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.